Table 2 Estimates of the impact of covariates on peak anti-CSP antibody titre following the final vaccine dose

Children (>3 months and <5 years)

2.59 (2.27, 2.91)

<0.001

2.50 (2.12, 2.87)

<0.001

Infants (<3 months)

- 0.49(−0.96, −0.02)

0.04

- 0.41 (−0.91, 0.09)

0.11

Adults (>18 years)

- 1.33 (−1.95, −0.69)

0.002

- 1.18 (−1.87, −0.48)

0.01

log₁₀(CSP_base)*children

0.05 (−0.04, 0.14)

0.28

- 0.03 (−0.14, 0.09)

0.66

log₁₀(CSP_base)*infants

- 0.58 (−0.76, −0.40)

<0.001

- 0.48 (−0.69, −0.27)

<0.001

log₁₀(CSP_base)*adults

0.24 (0.07, 0.41)

0.006

0.30 (0.11, 0.48)

0.002

Adjuvant (AS02 versus AS01)

- 0.13 (−0.20, −0.05)

<0.001

- 0.12 (−0.19, −0.05)

<0.001

Parasite prevalence

0.30 (−0.29, 0.89)

0.32

0.30 (−0.32, 0.93)

0.35

Doses (2 versus 3)

- 0.46 (−0.57, −0.36)

<0.001

- 0.47 (−0.57, −0.37)

<0.001

Schedule (017 m versus 012 m)

- 0.85 (−0.93, −0.77)

<0.001

- 0.84 (−0.92, −0.76)

<0.001

Co-administration

- 0.50 (−1.04, 0.03)

0.095

- 0.52 (−1.12, 0.07)

0.13

log₁₀(HBs_base)*children

–

–

0.05 (0.02, 0.09)

0.005

log₁₀(HBs_base)*infants

–

–

- 0.04 (−0.14, 0.05)

0.34

log₁₀(HBs_base)*adults

–

–

- 0.12 (−0.20, −0.04)

0.002